Metastatic paraganglioma

Seminars in Oncology

Volumn 37, Issue 6, 2010, Pages 627-637

  Fliedner, Stephanie M J ^a   Lehnert, Hendrik ^b   Pacak, Karel ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 6 FLUORODOPA F 18; 6 FLUORODOPAMINE F 18; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DACARBAZINE; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; INTERLEUKIN 13; OCTREOTIDE; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; TUMOR MARKER; ULTRATRACE IOBENGUANE I 131; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; IMAGE ANALYSIS; LIVER METASTASIS; LOW DRUG DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; PARAGANGLIOMA; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SYMPTOM; TUMOR LOCALIZATION;

ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; PARAGANGLIOMA; POSITRON-EMISSION TOMOGRAPHY; SUCCINATE DEHYDROGENASE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650249658     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.10.017     Document Type: Article

References (111)

1. F. Frnkel Ein Fall von doppelseitigem, vllig latent verlaufenen Nebennierentumor und gleichzeitiger Nephritis mit Vernderungen am Circulationsapparat und Retinitis Virchows Arch 103 1886 244 263
2. K. Pacak, G. Eisenhofer, and H. Ahlman Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005 Nat Clin Pract Endocrinol Metab 3 2007 92 102
3. D.S. O'Riordain, F. William, J. Young, C.S. Grant, J.A. Carney, and J.A. Heerden Clinical spectrum and outcome of functional extraadrenal paraganglioma World J Surg 20 1996 916 922
4. G. Opocher, F. Schiavi, and M. Iacobone Familial nonsyndromic pheochromocytoma Ann N Y Acad Sci 1073 2006 149 155
5. J. Bryant, J. Farmer, L.J. Kessler, R.R. Townsend, and K.L. Nathanson Pheochromocytoma: the expanding genetic differential diagnosis J Natl Cancer Inst 95 2003 1196 1204
6. J.W. Lenders, G. Eisenhofer, M. Mannelli, and K. Pacak Phaeochromocytoma Lancet 366 2005 665 675
7. H.-X. Hao, O. Khalimonchuk, and M. Schraders SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma Science 325 2009 1139 1142
8. J.P. Bayley, H.P. Kunst, and A. Cascon SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma Lancet Oncol 11 2010 366 372
9. Y. Qin, L. Yao, and E.E. King Germline mutations in TMEM127 confer susceptibility to pheochromocytoma Nat Genet 42 2010 229 233
10. J. Gaal, N. Burnichon, and E. Korpershoek Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas J Clin Endocrinol Metab 95 2010 1274 1278
11. C. Ladroue, R. Carcenac, and M. Leporrier PHD2 mutation and congenital erythrocytosis with paraganglioma N Engl J Med 359 2008 2685 2692
12. M. Mannelli, M. Castellano, and F. Schiavi Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas J Clin Endocrinol Metab 94 2009 1541 1547
13. L. Amar, J. Bertherat, and E. Baudin Genetic testing in pheochromocytoma or functional paraganglioma J Clin Oncol 23 2005 8812 8818
14. A.P. Gimenez-Roqueplo, H. Lehnert, and M. Mannelli Phaeochromocytoma, new genes and screening strategies Clin Endocrinol (Oxf) 65 2006 699 705
15. A.P. Gimenez-Roqueplo, J. Favier, and P. Rustin Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas Cancer Res 63 2003 5615 5621
16. H.J. Timmers, A. Kozupa, and G. Eisenhofer Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with SDHB-associated pheochromocytomas and paragangliomas J Clin Endocrinol Metab 92 2007 779 786
17. C.C. Boedeker, H.P. Neumann, W. Maier, B. Bausch, J. Schipper, and G.J. Ridder Malignant head and neck paragangliomas in SDHB mutation carriers Otolaryngol Head Neck Surg 137 2007 126 129
18. N. Burnichon, V. Rohmer, and L. Amar The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas J Clin Endocrinol Metab 94 2009 2817 2827
19. F.M. Brouwers, G. Eisenhofer, and J.J. Tao High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing J Clin Endocrinol Metab 91 2006 4505 4509
20. J.-P. Yu, and K. Pacak Management of malignant pheochromocytoma Endocrinologist 12 2002 291 299
21. H. Lehnert, J. Mundschenk, and K. Hahn Malignant pheochromocytoma Front Horm Res 31 2004 155 162
22. B. Havekes, J.A. Romijn, G. Eisenhofer, K. Adams, and K. Pacak Update on pediatric pheochromocytoma Pediatr Nephrol 24 2009 943 950
23. T.H. Pham, C. Moir, and G.B. Thompson Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center Pediatrics 118 2006 1109 1117
24. M. Barotini, G. Levin, and G. Sanso Characteristics of pheochromocytoma in a 4- to 20-year-old population Ann N Y Acad Sci 1073 2006 30 37
25. H.P. Neumann, B. Bausch, and S.R. McWhinney Germ-line mutations in nonsyndromic pheochromocytoma N Engl J Med 346 2002 1459 1466
26. A.O. Ciftci, F.C. Tanyel, M.E. Senocak, and N. Buyukpamukcu Pheochromocytoma in children J Pediatr Surg 36 2001 447 452
27. P.J. Hammond, D. Murphy, R. Carachi, D.F. Davidson, and D. McIntosh Childhood phaeochromocytoma and paraganglioma: 100% incidence of genetic mutations and 100% survival J Pediatr Surg 45 2010 383 386
28. H.K. Ganesh, S.V. Acharya, J. Goerge, T.R. Bandgar, P.S. Menon, and N.S. Shah Pheochromocytoma in children and adolescents Indian J Pediatr 76 2009 1151 1153
29. S. Lee, E. Nakamura, and H. Yang Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer Cancer Cell 8 2005 155 167
30. P.J. Pollard, J.J. Briere, and N.A. Alam Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations Hum Mol Genet 14 2005 2231 2239
31. M.A. Selak, S.M. Armour, and E.D. MacKenzie Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase Cancer Cell 7 2005 77 85
32. P.L. Dahia, K.N. Ross, and M.E. Wright A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas PLoS Genet 1 2005 72 80
33. P.L. Dahia, K. Hao, and J. Rogus Novel pheochromocytoma susceptibility loci identified by integrative genomics Cancer Res 65 2005 9651 9658
34. J. Favier, J.J. Briere, and N. Burnichon The Warburg effect is genetically determined in inherited pheochromocytomas PLoS One 4 2009 e7094
35. F.A. Mack, W.K. Rathmell, A.M. Arsham, J. Gnarra, B. Keith, and M.C. Simon Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth Cancer Cell 3 2003 75 88
36. K. Kondo, W.Y. Kim, M. Lechpammer, and W.G. Kaelin Jr Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth PLoS Biol 1 2003 E83
37. M.A. Hoffman, M. Ohh, H. Yang, J.M. Klco, M. Ivan, and W.G. Kaelin Jr von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF Hum Mol Genet 10 2001 1019 1027
38. P.L. Dahia Transcription association of VHL and SDH mutations link hypoxia and oxidoreductase signals in pheochromocytomas Ann N Y Acad Sci 1073 2006 208 220
39. U. Srirangalingam, B. Khoo, and L. Walker Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours J Endocr Relat Cancer 16 2009 515 525
40. L. Amar, E. Baudin, and N. Burnichon Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas J Clin Endocrinol Metab 92 2007 3822 3828
41. P.J. Pollard, M. El-Bahrawy, and R. Poulsom Expression of HIF-1{alpha}, HIF-2{alpha} (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations J Clin Endocrinol Metab 91 2006 4593 4598
42. A.P. Gimenez-Roqueplo, J. Favier, and P. Rustin Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma J Clin Endocrinol Metab 87 2002 4771 4774
43. T. Ishii, K. Yasuda, A. Akatsuka, O. Hino, P.S. Hartman, and N. Ishii A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis Cancer Res 65 2005 203 209
44. N. Ishii, T. Ishii, and P.S. Hartman The role of the electron transport SDHC gene on lifespan and cancer Mitochondrion 7 2007 24 28
45. E.H. Smith, R. Janknecht, and L.J. Maher III Succinate inhibition of {alpha}-ketoglutarate-dependent enzymes in a yeast model of paraganglioma Hum Mol Genet 16 2007 3136 3148
46. R.D. Guzy, B. Sharma, E. Bell, N.S. Chandel, and P.T. Schumacker Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis Mol Cell Biol 28 2008 718 731
47. A.M. Cervera, N. Apostolova, F.L. Crespo, M. Mata, and K.J. McCreath Cells silenced for SDHB expression display characteristic features of the tumor phenotype Cancer Res 68 2008 4058 4067
48. M. Bornemann, S.C. Hill, and G.S. Kidd 2nd Lactic acidosis in pheochromocytoma Ann Intern Med 105 1986 880 882
49. M.J. You, D.H. Castrillon, and B.C. Bastian Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice Proc Natl Acad Sci U S A 99 2002 1455 1460
50. N.B. Kiss, J. Geli, and F. Lundberg Methylation of the p16INK4A promoter is associated with malignant behavior in abdominal extra-adrenal paragangliomas but not pheochromocytomas Endocr Relat Cancer 15 2008 609 621
51. J. Geli, N. Kiss, and M. Karimi Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior Clin Cancer Res 14 2008 2551 2559
52. K. Pacak, J.W. Lenders, and G. Eisenhofer Pheochromocytoma: Diagnosis, Localisation and Treatment 2007 Blackwell Publishing Malden, MA
53. G. Eisenhofer, S.R. Bornstein, and F.M. Brouwers Malignant pheochromocytoma: current status and initiatives for future progress Endocr Relat Cancer 11 2004 423 436
54. E. Carlsen, Z. Abdullah, S.M. Kazmi, and G. Kousparos Pheochromocytomas, PASS, and immunohistochemistry Horm Metab Res 41 2009 715 719
55. E.E. Elder, D. Xu, and A. Hoog KI-67 and hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma Mod Pathol 16 2003 246 255
56. S.M. Tavangar, and A. Shojaee Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma Pathol Res Pract 206 2010 305 309
57. L.D. Thompson Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases Am J Surg Pathol 26 2002 551 566
58. D. Wu, A.S. Tischler, and R.V. Lloyd Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score Am J Surg Pathol 33 2009 599 608
59. F.H. van Nederveen, J. Gaal, and J. Favier An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis Lancet Oncol 10 2009 764 771
60. P.M. Sadow, K.M. Rumilla, L.A. Erickson, and R.V. Lloyd Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors Endocr Pathol 19 2008 97 103
61. V. Hayry, K. Salmenkivi, J. Arola, P. Heikkila, C. Haglund, and H. Sariola High frequency of SNAIL-expressing cells confirms and predicts metastatic potential of phaeochromocytoma Endocr Relat Cancer 16 2009 1211 1218
62. J. Waldmann, E.P. Slater, and P. Langer Expression of the transcription factor snail and its target gene twist are associated with malignancy in pheochromocytomas Ann Surg Oncol 16 2009 1997 2005
63. K. Pacak, and G. Eisenhofer An assessment of biochemical tests for the diagnosis of pheochromocytoma Nat Clin Pract Endocrinol Metab 3 2007 744 745
64. J.W. Lenders, J.J. Willemsen, and G. Eisenhofer Is supine rest necessary before blood sampling for plasma metanephrines? Clin Chem 53 2007 352 354
65. H.J. Timmers, K. Pacak, and T.T. Huynh Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene J Clin Endocrinol Metab 93 2008 4826 4832
66. G. Eisenhofer, D.S. Goldstein, and P. Sullivan Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine J Clin Endocrinol Metab 90 2005 2068 2075
67. N. van Duinen, D. Steenvoorden, and I.P. Kema Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas J Clin Endocrinol Metab 95 2010 209 214
68. H.J. Timmers, M. Hadi, and J.A. Carrasquillo The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma J Nucl Med 48 2007 1599 1606
69. B. Havekes, K. King, E.W. Lai, J.A. Romijn, E.P. Corssmit, and K. Pacak New imaging approaches to phaeochromocytomas and paragangliomas Clin Endocrinol (Oxf) 72 2010 137 145
70. E.P. Krenning, D.J. Kwekkeboom, S. Pawels, L.K. Kvols, and J.C. Reubi Somatostatin receptor scintigraphy L.M. Freeman, Nuclear Medicine Annual 1995 1995 Raven Press New York 242 244
71. S. Cleary, F.M. Brouwers, and G. Eisenhofer Expression of the noradrenaline transporter and phenylethanolamine N-methyltransferase in normal human adrenal gland and phaeochromocytoma Cell Tissue Res 322 2005 443 453
72. G. Eisenhofer The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines Pharmacol Ther 91 2001 35 62
73. J. Epelbaum, J. Bertherat, and G. Prevost Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas J Clin Endocrinol Metab 80 1995 1837 1844
74. J.C. Reubi, B. Waser, and S. Khosla In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas J Clin Endocrinol Metab 74 1992 1082 1089
75. H.J. Timmers, A. Kozupa, and C.C. Chen Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma J Clin Oncol 25 2007 2262 2269
76. 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma J Clin Endocrinol Metab 94 2009 4757 4767
77. T. Zelinka, H.J. Timmers, and A. Kozupa Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations Endocr Relat Cancer 15 2008 311 323
78. 131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma J Clin Endocrinol Metab 88 2003 4083 4087
79. M. Fassnacht, M.C. Kreissl, D. Weismann, and B. Allolio New targets and therapeutic approaches for endocrine malignancies Pharmacol Ther 123 2009 117 141
80. T. Scholz, C. Schulz, S. Klose, and H. Lehnert Diagnostic management of benign and malignant pheochromocytoma Exp Clin Endocrinol Diabetes 115 2007 155 159
81. R. Adjalle, P.F. Plouin, K. Pacak, and H. Lehnert Treatment of malignant pheochromocytoma Horm Metab Res 41 2009 687 696
82. G.N. Zografos, G. Vasiliadis, A.N. Farfaras, C. Aggeli, and M. Digalakis Laparoscopic surgery for malignant adrenal tumors J Soc Laproendosc Surg 13 2009 196 202
83. K. Pacak Preoperative management of the pheochromocytoma patient J Clin Endocrinol Metab 92 2007 4069 4079
84. K. Pacak, T. Fojo, and D.S. Goldstein Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma J Natl Cancer Inst 93 2001 648 649
85. A.M. Venkatesan, J. Locklin, and E.W. Lai Radiofrequency ablation of metastatic pheochromocytoma J Vasc Interv Radiol 20 2009 1483 1490
86. P.J. Cozzi, R. Englund, and D.L. Morris Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors Cancer 76 1995 501 509
87. H. Keiser, D.S. Goldstein, J.L. Wade, F.L. Douglas, and S.D. Averbuch Treatment of malignant pheochromocytoma with combination chemotherapy Hypertension 1985
88. K. Nomura, H. Kimura, and S. Shimizu Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy J Clin Endocrinol Metab 94 2009 2850 2856
89. J. He, D. Makey, and T. Fojo Successful chemotherapy of hepatic metastases in a case of succinate dehydrogenase subunit B-related paraganglioma Endocrine 36 2009 189 193
90. H. Huang, J. Abraham, and E. Hung Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients Cancer 113 2008 2020 2028
91. E.L. Bravo, S.R. Kalmadi, and I. Gill Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report Horm Metab Res 41 2009 703 706
92. M.H. Kulke, K. Stuart, and P.C. Enzinger Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors J Clin Oncol 24 2006 401 406
93. H.R. Keiser, D.S. Goldstein, J.L. Wade, F.L. Douglas, and S.D. Averbuch Treatment of malignant pheochromocytoma with combination chemotherapy Hypertension 7 1985 I18 I24
94. 131I-MIBG): a comprehensive review of 116 reported patients J Endocrinol Invest 20 1997 648 658
95. S.D. Safford, R.E. Coleman, and J.P. Gockerman Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma Surgery 134 2003 956 962
96. 131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma J Clin Oncol 27 2009 4162 4168
97. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma Eur J Nucl Med Mol Imaging 35 2008 725 733
98. M. Shilkrut, R. Bar-Deroma, G. Bar-Sela, A. Berniger, and A. Kuten Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience Am J Clin Oncol 33 2010 79 82
99. R.E. Coleman, J.B. Stubbs, J.A. Barrett, M. de la Guardia, N. Lafrance, and J.W. Babich Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid Cancer Biother Radiopharm 24 2009 469 475
100. M. Lamarre-Cliche, A.P. Gimenez-Roqueplo, E. Billaud, E. Baudin, J.P. Luton, and P.F. Plouin Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma Clin Endocrinol (Oxf) 57 2002 629 634
101. J. Mundschenk, N. Unger, S. Schulz, V. Hollt, R. Steinke, and H. Lehnert Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy J Clin Endocrinol Metab 88 2003 5150 5157
102. M.R. Druce, G.A. Kaltsas, M. Fraenkel, D.J. Gross, and A.B. Grossman Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001) Horm Metab Res 41 2009 697 702
103. A. Chrisoulidou, G. Kaltsas, I. Ilias, and A.B. Grossman The diagnosis and management of malignant phaeochromocytoma and paraganglioma Endocr Relat Cancer 14 2007 569 585
104. A.M. Joshua, S. Ezzat, and S.L. Asa Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma J Clin Endocrinol Metab 94 2009 5 9
105. C. Jimenez, M.E. Cabanillas, and L. Santarpia Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors J Clin Endocrinol Metab 94 2009 386 391
106. K.-S. Park, J.-L. Lee, and H. Ahn Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma Jpn J Clin Oncol 39 2009 327 331
107. D.J. Gross, G. Munter, and M. Bitan The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R Endocr Relat Cancer 13 2006 535 540
108. E.W. Lai, B.H. Joshi, and L. Martiniova Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy J Clin Endocrinol Metab 94 2009 2952 2957
109. B.H. Joshi, C. Hogaboam, P. Dover, S.R. Husain, and R.K. Puri Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases Vitam Horm 74 2006 479 504
110. K.S. King, M.A. Whatley, and D.K. Alexopoulos The use of functional imaging in a patient with head and neck paragangliomas J Clin Endocrinol Metab 95 2010 481 482
111. 131I-MIBG) Ann N Y Acad Sci 1073 2006 465 490